Bisoprolol in the treatment of chronic heart failure: From pathophysiology to clinical pharmacology and trial results

Therapeutics and Clinical Risk Management

Volumn 3, Issue 4, 2007, Pages 569-578

  Metra, Marco ^a   Nodari, Savina ^a   Bordonali, Tania ^a   Milani, Patrizia ^a   Lombardi, Carlo ^a   Bugatti, Silvia ^a   Fontanella, Benedetta ^a   Verzura, Giulia ^a   Danesi, Rossella ^a   Cas, Livio Dei ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Beta blockers; Bisoprolol; Heart failure

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN II; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CYTOKINE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NORADRENALIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADRENERGIC STIMULATION; ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; ASTHMA; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE MEASUREMENT; BRADYCARDIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE CARDIOMYOPATHY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FIRST PASS EFFECT; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HEART RATE VARIABILITY; HUMAN; HYPOTENSION; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; MORTALITY; NORADRENALIN BLOOD LEVEL; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SURVIVAL TIME;

EID: 34848828525     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Baxter AJ, Spensley A, Hildreth, et al. 2002. Beta-blockers in older persons with HF: tolerability and impact on quality of life. Heart, 88:611-14.
2. Belenkov IuN, Skvortsov AA, Mareev Vlu, et al. 2003. Clinical, hemodynamic and neuorohumoral effects of long-term therapy of patients with severe chronic heart failure with beta-adrenoblocker bisoprolol. Kardiologiia, 43:10-12.
3. Bolger AP, Al-Nasser F. 2003. Beta-blockers for chronic HF: surviving longer but feeling better? Int Cardiol, 92:1-8.
4. Bristow MR. 2000. Beta-adrenergic receptor blockade in chronic heart failure. Circulation, 101:558-69.
5. CIBIS-II Investigators and Committees. 1999. The Cardiac Insufficiency Bisoprolol Study: a randomised trial. Lancet, 353:9-13.
6. Campbell DJ, Aggarwal A, Esler M, et al. 2001. Beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet, 358:1609-10.
7. CIBIS Investigators and Committees 1994. A Randomized Trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation, 90:1765-73.
8. Cleland JG, Khand A, Clark A. 2001. The heart failure epidemic: exactly how big is it? Eur Heart J, 22:623-6.
9. Cleland JG, Coletta AP, Lammiman M, et al. 2005. Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. Eur J Heart Fail, 7:1070-5.
10. Communal C, Singh K, Pimentel DR, et al. 1998. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation, 98:1329-34.
11. Copie X, Pousset F, Lechat P, et al. 1996. Effects of β-blockade with bisoprolol on heart rate variability in advanced heart failure: Analysis of scatterplots or R-R intervals at selected heart rates. Am Heart J, 132:369-75.
12. Cowie MR, Mosterd A, Wood DA, et al. 1997. The epidemiology of heart failure. Eur Heart J, 18:208-25.
13. Dickstein K. 2006. Clinical trials update from the European Society of Cardiology Meeting 2005: CIBIS-III. Response to correspondence from R. Willenheimer et al. Eur J Heart Fail, 8:221-2.
14. Dubach P, Myers J, Bonetti P, et al. 2002. Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patents with heart failure: analysis with magnetic resonance myocardial tagging. Am Heart J, 143:676-83.
15. Erdmann E, Lechat P, Verkenne P, et al. 2001. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patients groups with chronic heart failure. Eur J Heart Fail, 3:469-79.
16. Francis GS, Benedict C, Johnstone, et al. 1990. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation, 82:1724-9.
17. Galatius S, Gustafsson F, Atar D, et al. 2004. Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive HF- A Randomized comparison. Cardiology, 102:160-5.
18. Gattis WA, O'Connor CM, Gallup DS, et al. 2004. IMPACT-HF Investigators and Coordinators. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment Of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol, 43:1534-41.
19. Hall SA, Cigarroa CG, Marcoux L, et al. 1995. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol, 25:11 54-61.
20. Hunt SA, Abraham WT, Chin MH, et al, ACC/AHA. 2005. Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 112:e154-235.
21. Ichihara S, Yamada Y, Ichihara G, et al. 2006. Attenuation of oxidative stress and cardiac dysfunction by bisoprolol in an animal model of dilated cardiomyopathy. Biochem Biophys Res Commun, 350:105-13.
22. Lechat P, Escolano S, Golmard JL, et al. 1997. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation, 96:2197-205.
23. Lechat P, Hulot JS, Escolano S, et al. 2001. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation, 103:1428-33.
24. Lechat P, Packer M, Chalon S, et al. 1998. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation, 98:1184-91.
25. Leier CV. 2004. Dismantling mandates in the treatment of heart failure. J Am Coll Cardiol, 44:1831-3.
26. Leizorovicz A, Lechat P, Cucherat M. 2002. Bisoprolol for treatment of chronic heart failure: A meta-analysis on individual data of two placebo-controlled studies-CIBIS and CIBIS II. Am Heart J, 143:301-7.
27. Le Jemtel TH, Padeletti M, Jelic S. 2007. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol, 49:171-80.
28. Leopold G, Kutz K. 1997. Bisoprolol: pharmacokinetic profile. Rev Contemp Pharmacother, 8:35-43.
29. Lowes BD, Gilbert EM, Abraham WT, et al. 2002. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med, 346:1357-65.
30. McMurray J, Cohen-Solal A, Dietz R, et al. 2005. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Fail, 7:710-21.
31. MERIT-HF Study Group. 1999. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive heart failure (MERIT-HF). Lancet, 353:2001-7.
32. Metra M, Dei Cas L, Cleland JG. 2006. Pharmacokinetic and pharmacodynamic characteristics of beta-blockers: When differences may matter. J Card Fail, 12:177-81.
33. Metra M, Dei Cas L, Di Lenarda A, et al. 2004. Beta-blockers in heart failure: are pharmacological differences clinically important? Heart Fail Rev, 9:123-30.
34. Metra M, Giubbini R, Nodari S, et al. 2000a. Differential effects of β-blockers in patients with heart failure. A prospective, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation, 102:546-551.
35. Metra M, Nardi M, Giubbini R, et al. 1994. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol, 24:1678-87.
36. Metra M, Nodari S, Bordonali T, et al. 2007. Beta-blocker therapy of heart failure: an update. Expert Opin Pharmacother, 8:289-98.
37. Metra M, Nodari S, D'Aloia A, et al. 1999. Beta blockers in heart failure: issues in the management of individual patients. Heart Fail Rev, 4:65-77.
38. Metra M, Nodari S, D'Aloia A, et al. 1998. Effects of neurohormonal antagonism on symptoms and quality of life in heart failure. Eur Heart J, 19(Suppl B):B25-35.
39. Metra M, Nodari S, D'Aloia A, et al. 2000b. A rationale for the use of beta-blockers as standard treatment for heart failure. Am Heart J, 139:511-21.
40. Metra M, Nodari S, Parrinello G, et al. 2003. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J, 145:292-9.
41. Metra M, Torp-Pedersen C, Swedberg K, et al. 2005. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J, 26:2259-68
42. Nyolczas N, Dékàny M, Fiòk J, et al. 2000. Prediction of the effect of bisoprolol in dilated cardiomyopathy. Cardiovasc Drugs Ther, 14:543-50.
43. Ohtsuka T, Hamada M, Hiasa G, et al. 2001. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol, 37:412-7.
44. Packer M, Coats A, Fowler M, et al. 2001. Effect of carvedilol on survival in severe chronic heart failure (COPERNICUS trial). N Engl J Med, 344:1651-8.
45. Pousset F, Copie X, Lechat P, et al. 1996. Effects of bisoprolol on heart variability in heart failure. Am J Cardiol, 7:612-7.
46. Remme WJ, Riegger G, Hildebrandt P, et al. 2004. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther, 18:57-66.
47. Remme WH, Torp-Pedersen C, Cleland JGF, et al. 2007. Carvedilol protects better against vascular events than metoprolol in heart failure - Results from COMET. J Am Coll Cardiol, 49:963-71.
48. Simon T, Mary-Krause M, Funch-Brentano C 2003. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart J, 24:552-9.
49. Sirak TE, Jelic S, Le Jemtel TH. 2004. Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol, 44:497-502.
50. Sliwa K, Norton GR, Kone N, et al. 2004. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. J Am Coll Cardiol, 44:1825-30.
51. Stewart S, MacIntyre K, Hole DJ, et al. 2001. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail, 3:315-22.
52. Swedberg K, Cleland J, Dargie H, et al. 2005. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J, 26:1115-40.
53. The CAPRICORN Investigators. 2001. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet, 357:1385-90.
54. von Haehling S, Genth-Zotz S, Bolger AP, et al. 2005. Effect of noradrenaline and isoproterenol on lipopolysaccharide-induced tumor necrosis factor-alpha production in whole blood from patients with chronic heart failure and the role of beta-adrenergic receptors. Am J Cardiol, 95:885-9.
55. Waagstein F, Bristow MR, Swedberg K, et al. 1993. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet, 342:1441-46.
56. Willenheimer R, Van Veldhuisen DJ, Silke B, et al. 2005. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence. Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation, 112:2426-35.
57. Willenheimer R, Krum H, van Veldhuisen DJ, et al. 2006. Comment on "Clinical trials update from the European Society of Cardiology meeting 2005: CIBIS-III, by JGF Cleland and others". Eur J Heart Fail, 8:219-20.
58. Willenheimer R. 2006. Hotline session at the World Congress of Cardiology/European Congress of Cardiology) in Barcelona.